Banner
    PI3Ks And BTK Inhibitors Will Still Be Economic Drivers Until 2016
    By News Staff | February 16th 2013 03:30 AM | Print | E-mail | Track Comments

    Heightened regulation, increased lawsuits and a resulting lack of venture capital has meant the western pharmaceutical industry faces a looming crisis but companies outside America and Europe may pick up the slack - new targets/drugs remain an evergreen medical idea elsewhere, especially to address the unmet need of drug resistance in the treatment of cancer.  

    Targeting kinases have been the target of most drug developers because they hold the key path to signaling, development and growth of the cell. Tumors/cancer biology indicates that this balance is disturbed and inhibiting the aberrant pathways in a balanced way is an approach to developing drugs against cancer. Resistance to existing therapies develops as cancer cells bypass these efforts and there remains an evergreen search for new targets to meet these challenges.

     Large global pharmaceutical companies see an opportunity for drugs with label expansion potential. About $10 billion has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies in the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and PI3K, BTKs inhibitors have led companies to try and focus on better treatment options for unmet need in hematologic malignancies.

    Unpartnered products will likely be acquired as mature data and approvals come in the next few years, acccording to market analysis by Bharatbook.